Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT01538433 Completed - IgA Nephropathy Clinical Trials

A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy

Start date: February 2012
Phase: N/A
Study type: Observational

This is a survey of factors which affect a pathologically defined early or delayed diagnosis of IgA nephropathy in Guangdong General Hospital, Guangzhou, China. An early or delayed diagnosis of IgA nephropathy is pathologically defined using the recently published Oxford classification of IgA nephropathy. The factors to be surveyed include health examination including urine test, socioeconomic status of patients including education,etc.

NCT ID: NCT01502579 Completed - IgA Nephropathy Clinical Trials

An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data

Start date: September 2011
Phase: N/A
Study type: Observational

The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function. This study is aimed to identify the potential relationship between pathological variants and clinical data in IgA nephropathy.

NCT ID: NCT01451710 Completed - IgA Nephropathy Clinical Trials

The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy

Start date: March 2011
Phase: N/A
Study type: Interventional

This is a single center,prospective,no-controlled clinical trial

NCT ID: NCT01392833 Completed - Clinical trials for Chronic Kidney Disease

Steroids and Azathioprine in Advanced IgAN

Start date: December 1999
Phase: Phase 3
Study type: Interventional

Some years ago the investigators designed a randomised trial to prospectively evaluate whether adding low-dose azathioprine (1.5 mg/kg/day for six months) to steroids (methylprednisolone 1 g i.v. for three consecutive days at months 1, 3 and 5, plus oral prednisone 0.5 mg/kg every other day for six months) can improve long-term renal survival in adult IgAN patients with proteinuria higher than 1g/24 hours and plasma creatinine <=2.0 mg/dl. In order to test the efficacy of the combination of steroids with azathioprine at various degree of renal function deterioration by extending the trial to patients with more advanced disease (serum creatinine higher or equal to 2 mg/dl) without any time limit for renal biopsy. Treatment will last one year: methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months, then 0.2 mg/kg every other day for further 6 months. The primary outcome was renal survival (a 50% increase in plasma creatinine from baseline); the secondary outcomes were proteinuria over time and the number and types of adverse events in the two groups assessed every month for the first six months, every two months from the 6th to the 12th month and every three months thereafter. The planned duration of follow up is five years.

NCT ID: NCT01269021 Completed - Clinical trials for IgA Nephropathy (IgAN)

An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)

Start date: November 2010
Phase: N/A
Study type: Interventional

In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid . Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.

NCT ID: NCT01237028 Completed - IgA Nephropathy Clinical Trials

Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers

Start date: March 2011
Phase: N/A
Study type: Interventional

This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.

NCT ID: NCT01225445 Completed - Clinical trials for Normal Blood Pressure

Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial

Start date: April 2002
Phase: Phase 3
Study type: Interventional

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown. Since angiotensin-converting enzyme (ACE) inhibitors reduce proteinuria and retard the rate of decline of renal function in chronic proteinuric nephropathies, including IgA nephropathy. The investigators conduct a randomized control study to evaluate the efficacy of ACE inhibitor in the treatment of early IgA nephropathy. Sixty patients with biopsy-proven IgA nephropathy and minimal proteinuria are recruited. They will be randomized to ramipril for 5 years or no treatment. Blood pressure, proteinuria and renal function will be monitored. This study will explore the effects of ACE inhibitor in the treatment of early IgA nephropathy, which is a major cause of dialysis-dependent renal failure.

NCT ID: NCT01224028 Completed - IgA Nephropathy Clinical Trials

A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.

NCT ID: NCT01115426 Completed - Clinical trials for IGA Glomerulonephritis

Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis

Start date: January 1997
Phase: Phase 4
Study type: Interventional

This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.

NCT ID: NCT01103778 Completed - Clinical trials for Chronic Kidney Disease

Pilot Study of Velcade® in IgA Nephropathy

Start date: July 2010
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy. The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preservation of renal function, partial responders, relapse rate, and to study mechanistic assays to predict remission.